Supernus Pharmaceuticals Inc [SUPN] stock is trading at $45.07, up 1.69%. An important factor to consider is whether the stock is rising or falling in short-term value. The SUPN shares have gain 5.60% over the last week, with a monthly amount glided 34.74%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Supernus Pharmaceuticals Inc [NASDAQ: SUPN] stock has seen the most recent analyst activity on July 30, 2025, when Cantor Fitzgerald upgraded its rating to a Overweight but kept the price target unchanged to $42 for it. Previously, Cantor Fitzgerald downgraded its rating to Neutral on February 19, 2025, and dropped its price target to $36. On January 06, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $57 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $36 on September 11, 2024. In a note dated April 13, 2021, Jefferies upgraded an Buy rating on this stock and boosted its target price from $25 to $40.
Supernus Pharmaceuticals Inc [SUPN] stock has fluctuated between $29.16 and $45.60 over the past year. Currently, Wall Street analysts expect the stock to reach $42 within the next 12 months. Supernus Pharmaceuticals Inc [NASDAQ: SUPN] shares were valued at $45.07 at the most recent close of the market. An investor can expect a potential drop of -6.81% based on the average SUPN price forecast.
Analyzing the SUPN fundamentals
Supernus Pharmaceuticals Inc [NASDAQ:SUPN] reported sales of 665.12M for the trailing twelve months, which represents a drop of -1.71%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.06 and Total Capital is 0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 44.19 points at the first support level, and at 43.32 for the second support level. However, for the 1st resistance point, the stock is sitting at 45.52, and for the 2nd resistance point, it is at 45.98.
Ratios To Look Out For
For context, Supernus Pharmaceuticals Inc’s Current Ratio is 2.58. On the other hand, the Quick Ratio is 2.43, and the Cash Ratio is 0.51. Considering the valuation of this stock, the price to sales ratio is 3.80, the price to book ratio is 2.38 and price to earnings (TTM) ratio is 39.39.
Transactions by insiders
Recent insider trading involved Mottola Frank, SVP, Quality, GMP, Ops, IT, that happened on Aug 25 ’25 when 14000.0 shares were sold. Director, NEWHALL CHARLES W III completed a deal on Aug 25 ’25 to sell 1000.0 shares. Meanwhile, President, CEO Khattar Jack A. sold 1000.0 shares on Aug 25 ’25.
